Fred Mill has been involved with CellCyte as Director of Device Engineering since December 2007, and, since November of 2008, has helped refine CellCyte’s Interim Operating Plan. This plan defines how the Company will operate, with limited funding over the near term, to continue the commercialization of its bioreactor product. Mr. Mill’s appointment is the next of several planned appointments required to fully implement the Interim Operating Plan. CellCyte formally adopted the plan before the end of 2009.